Brief: Nicox: Partner Fera Pharmaceuticals Applies For Orphan Drug Designation For Naproxcinod

Nicox SA

02/04/2020 06:36

April 2 (Reuters) - Nicox SA  NCOX.PA :
    * REG-NICOX’S PARTNER FERA PHARMACEUTICALS FILES APPLICATION
FOR
ORPHAN DRUG DESIGNATION FOR NAPROXCINOD IN SICKLE-CELL DISEASE
    * IS ELIGIBLE TO POTENTIALLY RECEIVE A SINGLE $40 MILLION
SALES-BASED MILESTONE IF NAPROXCINOD REACHES $1 BILLION YEARLY
SALES IN THE U.S. AS WELL AS ROYALTIES OF 7% ON NET SALES OF
NAPROXCINOD IN THE U.S.
    * FERA IS RESPONSIBLE FOR ALL CLINICAL DEVELOPMENT,
MANUFACTURING,
REGULATORY AND COMMERCIALIZATION ACTIVITIES.

Source text for Eikon:  ID:nGNE6dS4hy 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))